Alembic Pharma USFDA approvals: 6 generic cancer drugs

What Alembic disclosed to investors

Alembic Pharmaceuticals has reported a series of US regulatory updates spanning oncology, diabetes and injectable therapies, highlighting both tentative and final approvals from the US Food and Drug Administration (USFDA). The latest disclosure includes a tentative approval for Palbociclib capsules, a drug used to treat a certain type of breast cancer. The company said the product is therapeutically equivalent to Pfizer Inc’s reference listed drug Ibrance Capsules.

Alongside Palbociclib, Alembic has also announced tentative approvals for Darolutamide tablets and Bosutinib tablets in specific strengths, and final approvals for products including dapagliflozin tablets, methotrexate injection, and doxorubicin hydrochloride liposome injection. These developments matter for investors because US approvals and tentative approvals shape a generic company’s near-term launch pipeline, the timing of revenue opportunities, and potential legal or patent-related risks.

Palbociclib capsules: tentative approval and litigation risk

Alembic said it has received tentative approval from the USFDA for its abbreviated new drug application (ANDA) for Palbociclib capsules in strengths of 75 mg, 100 mg, and 125 mg. The company stated that the approved product is therapeutically equivalent to the reference listed drug Ibrance Capsules of Pfizer.

But Alembic also flagged a critical constraint: it is currently in litigation with Pfizer in the District Court of Delaware. As a result, the company said the launch of Palbociclib capsules will depend on the outcome of the litigation. That detail is important because tentative approval, by itself, does not guarantee an immediate commercial launch in the US market.

Darolutamide tablets: tentative approval for prostate cancer

Alembic Pharmaceuticals has also secured tentative approval from the USFDA for its generic version of Darolutamide tablets, strength 300 mg. The company said the tentative approval is for the ANDA of Darolutamide tablets and that the product is therapeutically equivalent to Bayer HealthCare Pharmaceuticals Inc’s reference listed drug Nubeqa Tablets, 300 mg.

In its disclosure, Alembic noted Darolutamide is indicated for treatment of adult patients with different types of prostate cancer in combination with docetaxel. The broader context provided in the material also points to the scale of the opportunity, with the Darolutamide 300 mg tablet market referenced as being estimated at over USD 3.1 billion (also cited as USD 3.155 billion in another mention).

Bosutinib 400 mg: tentative approval via sANDA

Alembic said it received tentative approval from the USFDA for its supplemental abbreviated new drug application (sANDA) for Bosutinib tablets, 400 mg. The company stated that the approved filing is therapeutically equivalent to the reference listed drug Bosulif tablets, 400 mg, marketed by PF Prism C.V.

The company also outlined Bosutinib’s indicated use in certain types of chronic myelogenous leukemia (CML). Specifically, it is indicated for adult patients with chronic phase Ph+ CML who are newly diagnosed or resistant or intolerant to prior therapy. It is also used for adult patients with accelerated or blast phase Ph+ CML with resistance or intolerance to prior therapy.

Alembic further noted it has already secured final USFDA approvals for Bosutinib tablets in 100 mg and 500 mg strengths, positioning the 400 mg strength as an additional opportunity within the molecule’s lifecycle.

Dapagliflozin tablets: final approval and shared exclusivity

In a separate regulatory update, Alembic Pharmaceuticals said it has received final approval from the USFDA for its generic version of dapagliflozin tablets used to control blood sugar levels in people with type-2 diabetes. The approval is for the ANDA of dapagliflozin tablets in strengths of 5 mg and 10 mg.

Alembic said the approved ANDA is therapeutically equivalent to AstraZeneca AB’s reference listed drug Farxiga Tablets, 5 mg and 10 mg. The company also stated it was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for these strengths. With the final approval, Alembic said it is eligible for 180 days of shared generic drug marketing exclusivity.

Methotrexate injection: final approval for oncology and arthritis

Alembic Pharmaceuticals said it has received final approval from the USFDA for its generic version of methotrexate injection used in the treatment of different types of cancers and arthritis. The final approval is for the ANDA of Methotrexate injection in strengths of 50 mg/2 ml multi-dose vials and 1g/40 ml single-dose vials.

The company stated the approved ANDA is therapeutically equivalent to the reference listed drug methotrexate injection (50 mg/2 ml multi-dose vials and 1g/40 ml single-dose vials) of Hospira, Inc. Alembic also listed several indications, including neoplastic diseases such as acute lymphoblastic leukemia and meningeal leukemia, and use in osteosarcoma, breast cancer, and squamous cell carcinoma of the head and neck.

Doxorubicin hydrochloride liposome injection: final approval

Alembic Pharmaceuticals said it has received final USFDA approval for its generic Doxorubicin Hydrochloride Liposome injection used in different types of cancer. The approval covers strengths of 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials.

The company said the approved ANDA is therapeutically equivalent to the reference listed drug Doxil Liposome Injection, 20 mg/10 mL and 50 mg/25 mL, of Baxter Healthcare Corporation. Alembic added that the injection is indicated for ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma.

What “tentative approval” means in these updates

The material also explains that tentative approval indicates a product meets USFDA requirements for quality, safety and efficacy, but cannot be marketed in the US until patent-related barriers are cleared. In practical terms, that means commercial timing can depend on patent expiry, successful patent challenges, or litigation outcomes.

This is directly relevant for Palbociclib, where Alembic explicitly said it is in litigation with Pfizer and that the launch depends on the court outcome. It is also relevant for Darolutamide and Bosutinib, where tentative approval signals regulatory readiness but not necessarily immediate market entry.

Key regulatory actions: summary table

Market impact and why the filings matter

For Alembic, each approval or tentative approval expands the addressable portfolio in the US, particularly in oncology where complex generics can require strong compliance and manufacturing capabilities. The disclosures also show a mix of outcomes: final approvals that allow commercialisation subject to routine launch planning, and tentative approvals that may still be gated by patents or litigation.

The Palbociclib update highlights how legal outcomes can influence launch timelines, even after a positive USFDA regulatory decision. The dapagliflozin update is notable because Alembic said it is eligible for 180 days of shared generic drug marketing exclusivity, a factor that can shape early competition dynamics. Meanwhile, the set of oncology-related updates across Darolutamide, Bosutinib, methotrexate, and doxorubicin liposome injection underlines a clear focus on cancer therapies.

Conclusion

Alembic Pharmaceuticals’ latest USFDA updates combine tentative approvals for Palbociclib, Darolutamide and Bosutinib with final approvals for dapagliflozin tablets, methotrexate injection and doxorubicin hydrochloride liposome injection. The near-term commercial impact will differ by product, particularly where tentative approval status and ongoing litigation can determine launch timing. Investors will watch for any further disclosures on the Pfizer litigation in Delaware and for launch-related updates tied to products with final approvals.